Skip to content

    Navin Fluorine International Q1 FY27 earnings call

    NAVINFLUOR
    Chemicals·5 Aug 2026
    Management Summary

    Navin Fluorine International Limited reported a robust Q1 FY27, with strong double-digit growth across revenue, EBITDA, and PAT. The company achieved a net debt-free status and continued its strategic investments in advanced materials and CDMO capacity expansion. Management highlighted strong performance in all business verticals and a positive outlook driven by a diversified product pipeline and customer relationships.

    Highlights

    5

    • Consolidated revenue grew 44% YoY to INR 1,045 crores, reflecting strong performance across all business verticals.

    • Operating EBITDA increased 73% YoY to INR 357 crores, with the margin expanding by 566 bps to 34.2%.

    • Profit After Tax (PAT) registered a significant growth of 108% YoY to INR 243 crores.

    • The company achieved a net debt-free status during the quarter, supported by INR 173 crores in operating cash flows.

    • Board approved new capex of INR 90 crores for advanced materials and initiated INR 125 crores for CDMO Phase 2 cGMP4, signaling future growth.

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹1,045 Cr+44%YoY
    2. 02Operating EBITDA₹357 Cr+73%YoY
    3. 03Operating EBITDA Margin34.2%
    4. 04Operating PBT₹283 Cr+101%YoY
    5. 05PAT₹243 Cr+108%YoY

    Segment breakdown

    • HPP Business₹540 Cr51.7%
    • Specialty Chemicals₹325 Cr31.1%
    • CDMO Business₹180 Cr17.2%
    Donut· Share of Revenue

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    internal accruals

    Debt

    Net ₹0 crores

    Liquidity

    Liquidity disclosed

    Company became net debt free during the quarter with operating cash flows of INR 173 crores.

    Guidance & targets

    9
    CategoryTargetPriority
    Capex
    Advanced Materials Adoption Capacities Capex Completion
    Q2 FY28
    		High
    Capex
    Chemours Project Completion
    End of Q2 FY27
    		High
    Capex
    CDMO Phase 2 cGMP4 Operationalization
    Q4 FY27
    		High
    Capacity
    HFC Capacity Expansion Commissioning
    Q3 FY27
    		High
    Capacity
    MPP Capacity Debottlenecking Completion
    Q3 FY27
    		High
    Sustainability
    Renewable Energy Contribution
    >60%
    		High
    CDMO
    Molecules with FDA Readout
    3-4 molecules
    		Medium
    Margins
    Operating EBITDA Margin
    32-33% +/- 1%
    		Medium
    HPP
    R32 Capacity Contracted
    35-45%
    		Medium

    What to watch in Q2 FY27

    5

    Advanced Materials Commercialization Progress

    Next quarter / mid-last quarter of FY
    Current4-5 products qualified, capex initiated for adoption capacities
    TargetProgress on commercialization and qualification of new products, completion of first phase of capex

    Why it matters

    Key to unlocking growth potential in a new high-margin vertical and validating strategic investments.

    So the adoption capacities we are putting out in two phases with the idea that the first phase of the capex will be complete more towards kind of the middle of last quarter of this financial year. And therefrom, that should allow us to start doing qualification of commercial sale quantities with customers, which then should open up the funnel for further capex and accelerate the growth.

    Risks & concerns

    3
    RiskSeverity

    R32 Pricing Volatility

    Analyst raised concerns about R32 pricing, which management acknowledged is not in their control. However, they emphasized their strategy to be the most competitive cost manufacturer through integrated value chain, productivity, and hybrid power, along with long-term demand being constructive. — Analyst acknowledged

    medium

    Agchem Pricing Pressure

    Management noted continued pricing pressure in the agchem market, especially in LatAm. Their strategy to mitigate this involves increasing footprint into innovators' pipeline and broadening the customer base with new, often patented, molecules. — Management acknowledged

    medium

    CDMO Molecule Readout Failures

    Management acknowledged that not all CDMO molecules will succeed, stating it's 'part of the game.' They mitigate this risk by maintaining a diversified portfolio with 30-40 molecules in the pipeline, including 3-4 expected for FDA readout in the next 8-12 months. — Analyst acknowledged

    low

    Q&A highlights

    7

    “The idea here, Ankur, is that this vertical will focus on niche sort of applications in high-growth sectors, mainly data centers, electronics, defense and semiconductors and will more specifically cater to applications that support the chip fabrication process, chip cooling process, manufacturing of display, OLEDs, data centers. We've also talked about fire suppressants, which have applications in data center as well as beyond, high-voltage electrical applications as well and new energy sort of wind applications, which will again focus on high purity HF, et cetera. That will come in, in due course.”

    Provides detailed strategic direction and target applications for the new advanced materials business, clarifying its high-growth, high-margin potential.

    asked by Ankur from Axis Capital

    2 min read6 chapters

    Detailed Narrative

    01

    Strong Q1 FY27 Financial Performance

    Navin Fluorine International Limited delivered a robust financial performance in Q1 FY27. Consolidated revenue surged by 44% year-on-year to INR 1,045 crores. Operating EBITDA witnessed a significant increase of 73% year-on-year, reaching INR 357 crores, with the operating EBITDA margin expanding by 566 basis points to 34.2%. Profit After Tax (PAT) also saw substantial growth of 108% year-on-year, totaling INR 243 crores, reflecting the strength of the company's portfolio and disciplined execution.

    02

    Strategic Expansion in Advanced Materials

    The company is strategically building its advanced materials business, focusing on high-growth sectors like data centers, electronics, semiconductors, and defense. The Board approved a new capex of INR 90 crores, funded by internal accruals, for adoption capacities to commercialize indigenous products. A notable achievement is the partnership with DRDO for a critical indigenous specialty material, underscoring Navin's commitment to 'Atmanirbhar Bharat' and aiming for meaningful contributions over the medium to long term.

    03

    CDMO Business Momentum and Pipeline

    The CDMO business continued its strong momentum, reporting an 82% year-on-year revenue growth to INR 180 crores. The company initiated Phase 2 of its cGMP4 capex, a INR 125 crores investment expected to be operational by Q4 FY27, which will deepen its relationship with a European CDMO partner. Management is actively working on a pipeline of 30-40 molecules, with 10 in late-stage development and 3-4 expected to receive FDA readouts within the next 8-12 months, showcasing a robust future growth trajectory.

    04

    HPP and Specialty Chemicals Growth Drivers

    The HPP business recorded a 33% year-on-year revenue growth to INR 540 crores, driven by healthy volume and improved realizations amidst a constructive pricing environment for HFCs. The specialty chemicals business grew 48% year-on-year to INR 325 crores, maintaining momentum through good order visibility for existing and new molecules. The company's strategy in specialty chemicals involves increasing its footprint in the innovators' pipeline and broadening its customer base, focusing on new, often patented, molecules to mitigate pricing pressures.

    05

    Ongoing Capex and Sustainability Initiatives

    Several key capex projects are progressing as planned. The HFC capacity expansion, adding 15,000 metric tons of R32 equivalent, is on track for commissioning in Q3 FY27. Similarly, MPP capacity expansion and debottlenecking activities at Dahej are expected to be completed by Q3 FY27. In a move towards sustainability, the company invested INR 15.73 crores in a group captive hybrid renewable project, aiming to meet over 60% of its energy requirements from renewable sources once operational.

    06

    Net Debt-Free Status and Future Outlook

    Navin Fluorine achieved a significant milestone by becoming net debt-free during the quarter, supported by strong operating cash flows of INR 173 crores. Management expressed optimism for the future, highlighting a strong pipeline of opportunities, multiple capacity expansion projects under execution, and robust customer engagements. The company remains focused on disciplined investment in technology, strengthening customer partnerships, and maintaining capital discipline to create sustainable long-term value for all stakeholders, with an EBITDA margin target of 32-33% +/- 1% for the next 1-2 years.

    This is an AI-generated summary of a publicly available earnings call transcript.